Is EQ or IMMX more profitable?

Equillium's return on equity of -61.43% beat Immix Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Equillium N/A -61.43% -53.72% Immix Biopharma N/A -64.24% -54.25%

Does the media prefer EQ or IMMX?

In the previous week, Immix Biopharma had 13 more articles in the media than Equillium. MarketBeat recorded 20 mentions for Immix Biopharma and 7 mentions for Equillium. Equillium's average media sentiment score of 1.56 beat Immix Biopharma's score of 0.22 indicating that Equillium is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Equillium 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Immix Biopharma 2 Very Positive mention(s) 1 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media refer more to AUTL or EQ?

In the previous week, Autolus Therapeutics had 16 more articles in the media than Equillium. MarketBeat recorded 23 mentions for Autolus Therapeutics and 7 mentions for Equillium. Equillium's average media sentiment score of 1.56 beat Autolus Therapeutics' score of 0.60 indicating that Equillium is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Autolus Therapeutics 4 Very Positive mention(s) 2 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Equillium 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Is STTK or EQ more profitable?

Shattuck Labs' return on equity of -58.09% beat Equillium's return on equity. Company Net Margins Return on Equity Return on Assets Shattuck Labs N/A -58.09% -53.74% Equillium N/A -61.43% -53.72%

Does the media prefer STTK or EQ?

In the previous week, Shattuck Labs had 10 more articles in the media than Equillium. MarketBeat recorded 17 mentions for Shattuck Labs and 7 mentions for Equillium. Equillium's average media sentiment score of 1.56 beat Shattuck Labs' score of 0.81 indicating that Equillium is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Shattuck Labs 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Equillium 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has preferable earnings & valuation, AGMB or EQ?

Equillium has higher revenue and earnings than AgomAb Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AgomAb Therapeutics N/A N/A -$70.77M N/A N/A Equillium $41.10M 3.63 -$22.40M -$0.32 N/A

Is AGMB or EQ more profitable?

AgomAb Therapeutics' return on equity of 0.00% beat Equillium's return on equity. Company Net Margins Return on Equity Return on Assets AgomAb Therapeutics N/A N/A N/A Equillium N/A -61.43% -53.72%

Does the media favor AGMB or EQ?

In the previous week, Equillium had 5 more articles in the media than AgomAb Therapeutics. MarketBeat recorded 7 mentions for Equillium and 2 mentions for AgomAb Therapeutics. Equillium's average media sentiment score of 1.56 beat AgomAb Therapeutics' score of 0.62 indicating that Equillium is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AgomAb Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Equillium 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has better valuation & earnings, EQ or RGNX?

Equillium has higher earnings, but lower revenue than REGENXBIO. Equillium is trading at a lower price-to-earnings ratio than REGENXBIO, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Equillium $41.10M 3.63 -$22.40M -$0.32 N/A REGENXBIO $174.48M 3.19 -$193.88M -$3.79 N/A

Is EQ or RGNX more profitable?

Equillium has a net margin of 0.00% compared to REGENXBIO's net margin of -112.58%. Equillium's return on equity of -61.43% beat REGENXBIO's return on equity. Company Net Margins Return on Equity Return on Assets Equillium N/A -61.43% -53.72% REGENXBIO -112.58% -220.07% -46.04%

Does the media refer more to EQ or RGNX?

In the previous week, REGENXBIO had 12 more articles in the media than Equillium. MarketBeat recorded 19 mentions for REGENXBIO and 7 mentions for Equillium. Equillium's average media sentiment score of 1.56 beat REGENXBIO's score of 0.69 indicating that Equillium is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Equillium 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive REGENXBIO 5 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Equillium (EQ) Competitors

$2.36 +0.35 (+17.41%)

Closing price 04:00 PM Eastern

Extended Trading

$2.29 -0.07 (-3.14%)

As of 05:44 PM Eastern

Compare

EQ vs. IMMX, AUTL, STTK, AGMB, and RGNX

Should you buy Equillium stock or one of its competitors? Equillium's main competitors and comparable companies include Immix Biopharma (IMMX), Autolus Therapeutics (AUTL), Shattuck Labs (STTK), AgomAb Therapeutics (AGMB), and REGENXBIO (RGNX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Equillium compare to Immix Biopharma?

Equillium (NASDAQ:EQ) and Immix Biopharma (NASDAQ:IMMX) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, earnings, institutional ownership, analyst recommendations, risk and dividends.

27.1% of Equillium shares are owned by institutional investors. Comparatively, 11.3% of Immix Biopharma shares are owned by institutional investors. 17.8% of Equillium shares are owned by insiders. Comparatively, 30.3% of Immix Biopharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Equillium has higher revenue and earnings than Immix Biopharma. Immix Biopharma is trading at a lower price-to-earnings ratio than Equillium, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Equillium	$41.10M	3.63	-$22.40M	-$0.32	N/A
Immix Biopharma	N/A	N/A	-$29.44M	-$0.88	N/A

Equillium has a beta of 1.82, suggesting that its stock price is 82% more volatile than the broader market. Comparatively, Immix Biopharma has a beta of 0.11, suggesting that its stock price is 89% less volatile than the broader market.

Equillium's return on equity of -61.43% beat Immix Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Equillium	N/A	-61.43%	-53.72%
Immix Biopharma	N/A	-64.24%	-54.25%

Equillium presently has a consensus price target of $7.57, suggesting a potential upside of 220.82%. Immix Biopharma has a consensus price target of $21.29, suggesting a potential upside of 94.04%. Given Equillium's stronger consensus rating and higher probable upside, research analysts plainly believe Equillium is more favorable than Immix Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Equillium	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.91
Immix Biopharma	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70

In the previous week, Immix Biopharma had 13 more articles in the media than Equillium. MarketBeat recorded 20 mentions for Immix Biopharma and 7 mentions for Equillium. Equillium's average media sentiment score of 1.56 beat Immix Biopharma's score of 0.22 indicating that Equillium is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Equillium	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Immix Biopharma	2 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

Equillium beats Immix Biopharma on 12 of the 15 factors compared between the two stocks.

How does Equillium compare to Autolus Therapeutics?

Autolus Therapeutics (NASDAQ:AUTL) and Equillium (NASDAQ:EQ) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their risk, media sentiment, valuation, dividends, analyst recommendations, earnings, profitability and institutional ownership.

Autolus Therapeutics has a beta of 2.07, indicating that its share price is 107% more volatile than the broader market. Comparatively, Equillium has a beta of 1.82, indicating that its share price is 82% more volatile than the broader market.

72.8% of Autolus Therapeutics shares are held by institutional investors. Comparatively, 27.1% of Equillium shares are held by institutional investors. 25.7% of Autolus Therapeutics shares are held by insiders. Comparatively, 17.8% of Equillium shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Equillium has a net margin of 0.00% compared to Autolus Therapeutics' net margin of -238.66%. Equillium's return on equity of -61.43% beat Autolus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Autolus Therapeutics	-238.66%	-152.15%	-47.27%
Equillium	N/A	-61.43%	-53.72%

Autolus Therapeutics presently has a consensus target price of $10.00, indicating a potential upside of 365.12%. Equillium has a consensus target price of $7.57, indicating a potential upside of 220.82%. Given Autolus Therapeutics' higher possible upside, equities research analysts clearly believe Autolus Therapeutics is more favorable than Equillium.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Autolus Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.88
Equillium	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.91

Equillium has lower revenue, but higher earnings than Autolus Therapeutics. Equillium is trading at a lower price-to-earnings ratio than Autolus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Autolus Therapeutics	$75.39M	7.59	-$287.53M	-$1.09	N/A
Equillium	$41.10M	3.63	-$22.40M	-$0.32	N/A

In the previous week, Autolus Therapeutics had 16 more articles in the media than Equillium. MarketBeat recorded 23 mentions for Autolus Therapeutics and 7 mentions for Equillium. Equillium's average media sentiment score of 1.56 beat Autolus Therapeutics' score of 0.60 indicating that Equillium is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Autolus Therapeutics	4 Very Positive mention(s)	2 Positive mention(s)	9 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Equillium	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

Autolus Therapeutics beats Equillium on 9 of the 16 factors compared between the two stocks.

How does Equillium compare to Shattuck Labs?

Shattuck Labs (NASDAQ:STTK) and Equillium (NASDAQ:EQ) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, media sentiment, profitability, valuation, risk and institutional ownership.

Equillium has higher revenue and earnings than Shattuck Labs. Shattuck Labs is trading at a lower price-to-earnings ratio than Equillium, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Shattuck Labs	$1M	568.97	-$48.81M	-$0.63	N/A
Equillium	$41.10M	3.63	-$22.40M	-$0.32	N/A

58.7% of Shattuck Labs shares are owned by institutional investors. Comparatively, 27.1% of Equillium shares are owned by institutional investors. 8.8% of Shattuck Labs shares are owned by company insiders. Comparatively, 17.8% of Equillium shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Shattuck Labs' return on equity of -58.09% beat Equillium's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Shattuck Labs	N/A	-58.09%	-53.74%
Equillium	N/A	-61.43%	-53.72%

Shattuck Labs has a beta of 1.08, meaning that its stock price is 8% more volatile than the broader market. Comparatively, Equillium has a beta of 1.82, meaning that its stock price is 82% more volatile than the broader market.

In the previous week, Shattuck Labs had 10 more articles in the media than Equillium. MarketBeat recorded 17 mentions for Shattuck Labs and 7 mentions for Equillium. Equillium's average media sentiment score of 1.56 beat Shattuck Labs' score of 0.81 indicating that Equillium is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Shattuck Labs	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Equillium	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Shattuck Labs currently has a consensus target price of $12.13, indicating a potential upside of 63.41%. Equillium has a consensus target price of $7.57, indicating a potential upside of 220.82%. Given Equillium's stronger consensus rating and higher probable upside, analysts clearly believe Equillium is more favorable than Shattuck Labs.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Shattuck Labs	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82
Equillium	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.91

Summary

Equillium beats Shattuck Labs on 11 of the 16 factors compared between the two stocks.

How does Equillium compare to AgomAb Therapeutics?

AgomAb Therapeutics (NASDAQ:AGMB) and Equillium (NASDAQ:EQ) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, dividends, analyst recommendations, media sentiment, profitability, risk, institutional ownership and valuation.

AgomAb Therapeutics presently has a consensus price target of $33.00, suggesting a potential upside of 149.62%. Equillium has a consensus price target of $7.57, suggesting a potential upside of 220.82%. Given Equillium's stronger consensus rating and higher probable upside, analysts plainly believe Equillium is more favorable than AgomAb Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AgomAb Therapeutics	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83
Equillium	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.91

In the previous week, Equillium had 5 more articles in the media than AgomAb Therapeutics. MarketBeat recorded 7 mentions for Equillium and 2 mentions for AgomAb Therapeutics. Equillium's average media sentiment score of 1.56 beat AgomAb Therapeutics' score of 0.62 indicating that Equillium is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AgomAb Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Equillium	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Equillium has higher revenue and earnings than AgomAb Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AgomAb Therapeutics	N/A	N/A	-$70.77M	N/A	N/A
Equillium	$41.10M	3.63	-$22.40M	-$0.32	N/A

AgomAb Therapeutics' return on equity of 0.00% beat Equillium's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AgomAb Therapeutics	N/A	N/A	N/A
Equillium	N/A	-61.43%	-53.72%

27.1% of Equillium shares are owned by institutional investors. 17.8% of Equillium shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Equillium beats AgomAb Therapeutics on 10 of the 12 factors compared between the two stocks.

How does Equillium compare to REGENXBIO?

Equillium (NASDAQ:EQ) and REGENXBIO (NASDAQ:RGNX) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, profitability, media sentiment, institutional ownership and earnings.

Equillium currently has a consensus target price of $7.57, indicating a potential upside of 220.82%. REGENXBIO has a consensus target price of $23.73, indicating a potential upside of 120.31%. Given Equillium's stronger consensus rating and higher possible upside, equities analysts clearly believe Equillium is more favorable than REGENXBIO.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Equillium	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.91
REGENXBIO	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.62

Equillium has a beta of 1.82, suggesting that its stock price is 82% more volatile than the broader market. Comparatively, REGENXBIO has a beta of 0.94, suggesting that its stock price is 6% less volatile than the broader market.

27.1% of Equillium shares are owned by institutional investors. Comparatively, 88.1% of REGENXBIO shares are owned by institutional investors. 17.8% of Equillium shares are owned by insiders. Comparatively, 14.2% of REGENXBIO shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, REGENXBIO had 12 more articles in the media than Equillium. MarketBeat recorded 19 mentions for REGENXBIO and 7 mentions for Equillium. Equillium's average media sentiment score of 1.56 beat REGENXBIO's score of 0.69 indicating that Equillium is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Equillium	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
REGENXBIO	5 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Equillium has higher earnings, but lower revenue than REGENXBIO. Equillium is trading at a lower price-to-earnings ratio than REGENXBIO, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Equillium	$41.10M	3.63	-$22.40M	-$0.32	N/A
REGENXBIO	$174.48M	3.19	-$193.88M	-$3.79	N/A

Equillium has a net margin of 0.00% compared to REGENXBIO's net margin of -112.58%. Equillium's return on equity of -61.43% beat REGENXBIO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Equillium	N/A	-61.43%	-53.72%
REGENXBIO	-112.58%	-220.07%	-46.04%

Summary

Equillium beats REGENXBIO on 11 of the 17 factors compared between the two stocks.

Get Equillium News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EQ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

EQ vs. The Competition

Export

Metric	Equillium	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$149.22M	$3.71B	$6.97B	$13.05B
Dividend Yield	N/A	3.76%	2.58%	10.72%
P/E Ratio	-7.38	10.68	269.86	25.30
Price / Sales	3.63	1,293.47	598.68	101.54
Price / Cash	N/A	103.01	70.53	50.75
Price / Book	5.02	17.49	13.08	6.33
Net Income	-$22.40M	-$13.32M	$3.45B	$347.70M
7 Day Performance	11.85%	1.77%	1.14%	1.08%
1 Month Performance	-14.49%	1.63%	1.81%	1.04%
1 Year Performance	140.79%	56.45%	67.69%	20.77%

Equillium Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
EQ Equillium	3.04 of 5 stars	$2.36 +17.4%	$7.57 +220.8%	+116.1%	$149.22M	$41.10M	N/A	40	News Coverage Positive News Earnings Report Analyst Upgrade
IMMX Immix Biopharma	2.8105 of 5 stars	$11.49 +13.4%	$21.29 +85.3%	+368.7%	$551.19M	N/A	N/A	9	Earnings Report Analyst Forecast Analyst Revision
AUTL Autolus Therapeutics	3.083 of 5 stars	$2.33 +12.6%	$8.75 +275.5%	+20.7%	$550.94M	$75.39M	N/A	330	Earnings Report Analyst Revision High Trading Volume
STTK Shattuck Labs	4.0073 of 5 stars	$7.18 +0.6%	$12.13 +68.9%	+802.9%	$547.50M	$1M	N/A	100	News Coverage Earnings Report Analyst Forecast Analyst Revision
AGMB AgomAb Therapeutics	2.393 of 5 stars	$14.85 -1.0%	$33.00 +122.2%	N/A	$543.55M	N/A	N/A	62

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:EQ) was last updated on 8/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Equillium (EQ) Competitors

EQ vs. IMMX, AUTL, STTK, AGMB, and RGNX

How does Equillium compare to Immix Biopharma?

Summary

How does Equillium compare to Autolus Therapeutics?

Summary

How does Equillium compare to Shattuck Labs?

Summary

How does Equillium compare to AgomAb Therapeutics?

Summary

How does Equillium compare to REGENXBIO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EQ vs. The Competition

Equillium Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Equillium (EQ) Competitors

EQ vs. IMMX, AUTL, STTK, AGMB, and RGNX

How does Equillium compare to Immix Biopharma?

Do institutionals & insiders hold more shares of EQ or IMMX?

Which has preferable earnings & valuation, EQ or IMMX?

Which has more volatility and risk, EQ or IMMX?

Is EQ or IMMX more profitable?

Do analysts prefer EQ or IMMX?

Does the media prefer EQ or IMMX?

Summary

How does Equillium compare to Autolus Therapeutics?

Which has more volatility & risk, AUTL or EQ?

Do institutionals and insiders have more ownership in AUTL or EQ?

Is AUTL or EQ more profitable?

Do analysts prefer AUTL or EQ?

Which has higher valuation & earnings, AUTL or EQ?

Does the media refer more to AUTL or EQ?

Summary

How does Equillium compare to Shattuck Labs?

Which has better valuation and earnings, STTK or EQ?

Do insiders and institutionals have more ownership in STTK or EQ?

Is STTK or EQ more profitable?

Which has more risk and volatility, STTK or EQ?

Does the media prefer STTK or EQ?

Do analysts prefer STTK or EQ?

Summary

How does Equillium compare to AgomAb Therapeutics?

Do analysts rate AGMB or EQ?

Does the media favor AGMB or EQ?

Which has preferable earnings & valuation, AGMB or EQ?

Is AGMB or EQ more profitable?

Do insiders & institutionals hold more shares of AGMB or EQ?

Summary

How does Equillium compare to REGENXBIO?

Do analysts prefer EQ or RGNX?

Which has more volatility and risk, EQ or RGNX?

Do institutionals & insiders have more ownership in EQ or RGNX?

Does the media refer more to EQ or RGNX?

Which has better valuation & earnings, EQ or RGNX?

Is EQ or RGNX more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EQ vs. The Competition

Equillium Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools